Engineering tumor-colonizing E. coli Nissle 1917 for detection and treatment of colorectal neoplasia

Abstract

Bioengineered probiotics enable new opportunities to improve colorectal cancer (CRC) screening, prevention and treatment. Here, first, we demonstrate selective colonization of colorectal adenomas after oral delivery of probiotic E. coli Nissle 1917 (EcN) to a genetically-engineered murine model of CRC predisposition and orthotopic models of CRC. We next undertake an interventional, double-blind, dual-centre, prospective clinical trial, in which CRC patients take either placebo or EcN for two weeks prior to resection of neoplastic and adjacent normal colorectal tissue (ACTRN12619000210178). We detect enrichment of EcN in tumor samples over normal tissue from probiotic-treated patients (primary outcome of the trial). Next, we develop early CRC intervention strategies. To detect lesions, we engineer EcN to produce a small molecule, salicylate. Oral delivery of this strain results in increased levels of salicylate in the urine of adenoma-bearing mice, in comparison to healthy controls. To assess therapeutic potential, we engineer EcN to locally release a cytokine, GM-CSF, and blocking nanobodies against PD-L1 and CTLA-4 at the neoplastic site, and demonstrate that oral delivery of this strain reduces adenoma burden by ~50%. Together, these results support the use of EcN as an orally-deliverable platform to detect disease and treat CRC through the production of screening and therapeutic molecules.

References 68

1. 1.

   Mazzolini, R. et al. Engineered live bacteria suppress Pseudomonas aeruginosa infection in mouse lung and dissolve endotracheal-tube biofilms. Nat. Biotechnol.41, 1089–1098 (2023).

   Not in our library10.1038/s41587-022-01584-9

2. 2.
   Intestinal transgene delivery with native E. coli chassis allows persistent physiological changes · 2022

   No notice
3. 3.

   Whitfill T, Oh J. Recoding the metagenome: microbiome engineering in situ. Curr. Opin. Microbiol. 2019;50:28-34.

   Not in our library10.1016/j.mib.2019.09.005

4. 4.

   Forbes NS. Engineering the perfect (bacterial) cancer therapy. Nat. Rev. Cancer. 2010;10:785-794.

   Not in our library10.1038/nrc2934

5. 5.

   Chien T, Doshi A, Danino T. Advances in bacterial cancer therapies using synthetic biology. Curr. Opin. Syst. Biol. 2017;5:1-8.

   Not in our library10.1016/j.coisb.2017.05.009

6. 6.
   Bacteria-cancer interactions: bacteria-based cancer therapy · 2019

   No notice
7. 7.

   Gurbatri CR, Arpaia N, Danino T. Engineering bacteria as interactive cancer therapies. Science. 2022;378:858-864.

   Not in our library10.1126/science.add9667

8. 8.
   Engineering bacterial thiosulfate and tetrathionate sensors for detecting gut inflammation · 2017

   No notice
9. 9.

   Mao N, Cubillos-Ruiz A, Cameron DE, Collins JJ. Probiotic strains detect and suppress cholera in mice. Sci. Transl. Med. 2018;10:eaao2586.

   Not in our library10.1126/scitranslmed.aao2586

10. 10.

    Robinson CM, Short NE, Riglar DT. Achieving spatially precise diagnosis and therapy in the mammalian gut using synthetic microbial gene circuits. Front. Bioeng. Biotechnol. 2022;10:959441.

    Not in our library10.3389/fbioe.2022.959441

11. 11.

    Munck C, Sheth RU, Freedberg DE, Wang HH. Recording mobile DNA in the gut microbiota using an Escherichia coli CRISPR-Cas spacer acquisition platform. Nat. Commun. 2020;11:95.

    Not in our library10.1038/s41467-019-14012-5

12. 12.

    Schmidt F, et al. Noninvasive assessment of gut function using transcriptional recording sentinel cells. Science. 2022;376:eabm6038.

    Not in our library10.1126/science.abm6038

13. 13.

    Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA: Cancer J. 2020;70:7-30.

    Not in our library10.3322/caac.21590

14. 14.

    Lin JS, et al. Screening for colorectal cancer: updated evidence report and systematic review for the US Preventive Services Task Force. Jama. 2016;315:2576-2594.

    Not in our library10.1001/jama.2016.3332

15. 15.

    Regula J, et al. Colonoscopy in colorectal-cancer screening for detection of advanced neoplasia. N. Engl. J. Med. 2006;355:1863-1872.

    Not in our library10.1056/nejmoa054967

16. 16.

    Kew GS, Koh CJ. Strategies to improve persistent adherence in colorectal cancer screening. Gut Liver. 2020;14:546.

    Not in our library10.5009/gnl19306

17. 17.

    Nian J, et al. Diagnostic accuracy of methylated SEPT9 for blood-based colorectal cancer detection: a systematic review and meta-analysis. Clin. Transl. Gastroenterol. 2017;8:e216.

    Not in our library10.1038/ctg.2016.66

18. 18.
    The performance of the SEPT9 gene methylation assay and a comparison with other CRC screening tests: A meta-analysis · 2017

    No notice
19. 19.

    Burn J, Sheth H. The role of aspirin in preventing colorectal cancer. Br. Med. Bull. 2016;119:17-24.

    Not in our library10.1093/bmb/ldw028

20. 20.
    Cancer prevention with aspirin in hereditary colorectal cancer (Lynch syndrome), 10-year follow-up and registry-based 20-year data in the CAPP2 study: a double-blind, randomised, placebo-controlled trial · 2020

    No notice
21. 21.
    Colorectal Carcinoma: A General Overview and Future Perspectives in Colorectal Cancer · 2017

    No notice
22. 22.

    Ahmed M. Colon cancer: a clinician’s perspective in 2019. Gastroenterol. Res. 2020;13:1.

    Not in our library10.14740/gr1239

23. 23.

    Germani MM, Moretto R. Immune checkpoint inhibitors in mismatch repair proficient/microsatellite stable metastatic colorectal cancer patients: Insights from the AtezoTRIBE and MAYA trials. Cancers. 2021;14:52.

    Not in our library10.3390/cancers14010052

24. 24.

    André T, et al. Pembrolizumab in microsatellite-instability–high advanced colorectal cancer. N. Engl. J. Med. 2020;383:2207-2218.

    Not in our library10.1056/nejmoa2017699

25. 25.

    Chalabi M, et al. Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers. Nat. Med. 2020;26:566-576.

    Not in our library10.1038/s41591-020-0805-8

26. 26.

    Zhang Y, et al. Escherichia coli Nissle 1917 targets and restrains mouse B16 melanoma and 4T1 breast tumors through expression of azurin protein. Appl. Environ. Microbiol. 2012;78:7603-7610.

    Not in our library10.1128/aem.01390-12

27. 27.

    Danino T, et al. Programmable probiotics for detection of cancer in urine. Sci. Transl. Med. 2015;7:289ra284-289ra284.

    Not in our library10.1126/scitranslmed.aaa3519

28. 28.
    Bioengineered Escherichia coli Nissle 1917 for tumour‐targeting therapy · 2020

    Not checked
29. 29.

    Zeineldin M, Neufeld KL. More than two decades of APC modeling in rodents. Biochim. Biophys. Acta (BBA) Rev. Cancer. 2013;1836:80-89.

    Not in our library10.1016/j.bbcan.2013.01.001

30. 30.

    Kwong, L. N. & Dove, W. F. APC and its modifiers in colon cancer. Adv. Exp. Med. Biol.656, 85–106 (2009).

    Not in our library10.1007/978-1-4419-1145-2_8

31. 31.

    Danino T, Lo J, Prindle A, Hasty J, Bhatia SN. In vivo gene expression dynamics of tumor-targeted bacteria. ACS Synth. Biol. 2012;1:465-470.

    Not in our library10.1021/sb3000639

32. 32.

    Din MO, et al. Synchronized cycles of bacterial lysis for in vivo delivery. Nature. 2016;536:81-85.

    Not in our library10.1038/nature18930

33. 33.

    Gurbatri CR, et al. Engineered probiotics for local tumor delivery of checkpoint blockade nanobodies. Sci. Transl. Med. 2020;12:eaax0876.

    Not in our library10.1126/scitranslmed.aax0876

34. 34.

    Pleguezuelos-Manzano C, et al. Mutational signature in colorectal cancer caused by genotoxic pks+ E. coli. Nature. 2020;580:269-273.

    Not in our library10.1038/s41586-020-2080-8

35. 35.
    Oligosaccharides increase the genotoxic effect of colibactin produced by pks+ Escherichia coli strains · 2021

    Not checked
36. 36.

    Wallenstein A, et al. ClbR is the key transcriptional activator of colibactin gene expression in Escherichia coli. MSphere. 2020;5:e00591-00520.

    Not in our library10.1128/msphere.00591-20

37. 37.

    Kalantari A, et al. Robust performance of a live bacterial therapeutic chassis lacking the colibactin gene cluster. PLoS One. 2023;18:e0280499.

    Not in our library10.1371/journal.pone.0280499

38. 38.
    Engineered E. coli Nissle 1917 for the delivery of matrix-tethered therapeutic domains to the gut · 2019

    No notice
39. 39.

    Ho CL, et al. Engineered commensal microbes for diet-mediated colorectal-cancer chemoprevention. Nat. Biomed. Eng. 2018;2:27-37.

    Not in our library10.1038/s41551-017-0181-y

40. 40.

    Grabig A, et al. Escherichia coli strain Nissle 1917 ameliorates experimental colitis via toll-like receptor 2-and toll-like receptor 4-dependent pathways. Infect. Immun. 2006;74:4075-4082.

    Not in our library10.1128/iai.01449-05

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.